A feasibility study of an aromatase inhibitor (Al), letrozole (L) and the antibody to vascular endothelial growth factor (VEGF), bevacizurnab (B), in patients (pts) with hormone receptor-positive metastatic breast cancer (MBC) Meeting Abstract
| Authors: | Traina, T. A.; Dickler, M. N.; Caravelli, J. F.; Yeh, B. M.; Brogi, E.; Panageas, K.; Flores, S. A.; Norton, L.; Hudis, C.; Rugo, H. |
| Abstract Title: | A feasibility study of an aromatase inhibitor (Al), letrozole (L) and the antibody to vascular endothelial growth factor (VEGF), bevacizurnab (B), in patients (pts) with hormone receptor-positive metastatic breast cancer (MBC) |
| Meeting Title: | 41st Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 23 |
| Issue: | 16 Suppl. |
| Meeting Dates: | 2005 May 13-17 |
| Meeting Location: | Orlando, FL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2005-06-01 |
| Start Page: | 76S |
| Language: | English |
| ACCESSION: | WOS:000230326600304 |
| PROVIDER: | wos |
| DOI: | 10.1200/jco.2005.23.16_suppl.796 |
| Notes: | --- - Meeting Abstract: 796 - 41st Annual Meeting of the American-Society-of-Clinical-Oncology - MAY 13-17, 2005 - Orlando, FL - S - Part 1 - "Source: Wos" |
Altmetric
Citation Impact
BMJ Impact Analytics
